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ABSTRACT
Impaired insulin secretion and action are important for development of type 2 diabetes (T2D) and
metabolic syndrome (MetS). Despite recognized heterogeneity of these glucometabolic disorders, few
data are available of biological variation in insulin secretion and action among individuals with T2D
and MetS. The aim of this study was to explore the inter-individual variations using gold standard
methods in a cross-sectional study of two independent cohorts of phenotypically well-characterized
subjects. Cohort I included 486 subjects with MetS, and cohort II 62 subjects with established T2D.
First phase insulin secretion was defined as the incremental area under the curve 0–8min (iAUC0–8min)
during an intravenous glucose tolerance test (IVGTT). Insulin sensitivity was measured as the insulin
sensitivity index (SI) modelled from IVGTT in cohort I, and in II as total glucose disposal (TGD) esti-
mated from a euglycaemic-hyperinsulinaemic clamp. Variation is given as total range and, fold-vari-
ation between 5%- and 95%-percentile. The iAUC0–8min ranged from 60 to 3397mUL1min1 among
subjects with MetS and from 263 to 1194mUL1min1 in subjects with T2D, representing a more
than 10-fold variation. Insulin sensitivity ranged from SI 0.19 to 15.29 (mU/L)
1min1 among subjects
with MetS and TGD 12.9–101.6 lmolkgFFM1min1 in subjects with T2D, representing a 6.8 and 5.5-
fold variation, respectively. The other components of MetS; BMI, waist-hip ratio, HDL-cholesterol, trigly-
cerides and blood pressure (BP), showed a 1.4–4.7-fold variation. In conclusion, our data demonstrated
extensive inter-individual variations in insulin secretion and sensitivity. These variations may be essen-
tial to take into account when planning clinical research and treatment in subjects with T2D
and MetS.
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Introduction
Type 2 diabetes (T2D) is considered to result from a com-
bination of insulin secretory dysfunction and insulin resist-
ance [1]. Insulin resistance is often associated with a
number of cardiovascular risk factors in a metabolic syn-
drome (MetS) characterized by hyperglycaemia, abdominal
adiposity, hypertension and dyslipidaemia [2]. During the
development of T2D, fasting and/or post-prandial glucose
levels most often increase gradually through states of
impaired fasting glucose or impaired glucose tolerance
before reaching manifest T2D [3]. The b-cell dysfunction in
T2D reflects insufficient adaptation to the increased demand
due to peripheral and hepatic insulin resistance [3]. Initially,
insulin resistance leads to elevated insulin secretion to main-
tain normal blood glucose levels [3]. When b-cells
decompensate, plasma insulin concentrations fall, glucose
concentrations increase and T2D develops [3]. Emerging
evidence also suggests that the process is accompanied by
loss of b-cells [4].
Whereas various in vivo tests of insulin sensitivity mostly
estimate the same phenomenon (insulin-driven flux of glu-
cose into cells), different in vivo tests of insulin secretion
explore very different aspects of b-cell function, and no sin-
gle test allows b-cell function to be assessed with accuracy
and specificity [1].
Kahn et al. [5] have pioneered the concept that a hyper-
bolic relationship exists between b-cell function and insulin
sensitivity [5]. The hyperbola hypothesis implies that the
product b-cell function x insulin sensitivity is nearly con-
stant, called the disposition index (DI) [5]. In response to
increasing insulin resistance, a compensatory increase in
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insulin secretion will normally maintain glucose tolerance,
but result in increased basal insulin levels and more pro-
nounced glucose-stimulated insulin responses. In T2D, the
pancreatic b-cells are unable to compensate for the increas-
ing insulin resistance. Plasma insulin levels will decrease
and the patients ‘fall off’ the hyperbolic curve [5].
Although the general pathogenic aspect assumed here
applies to groups of subjects, few studies have reported the
between-subject variation in insulin secretion and sensitivity
observed among individuals with prediabetes and T2D.
Thus, the aim of this study was to explore the inter-individ-
ual variation in different parameters of insulin secretion and
sensitivity measured in two cohorts of subjects across the
glucometabolic spectrum; cohort I consists of subjects with
MetS and cohort II subjects with established T2D.
Materials and methods
Subjects
To assess the inter-individual variations in insulin secretion
and insulin sensitivity we used data from two previously
established cohorts. Cohort I includes 486 subjects of
Caucasian ethnicity, aged 35–70 years, with BMI 20–40 kg/
m2, having MetS defined by three or more of the following
slightly modified National Cholesterol Education
Programme (NCEP) Adult Treatment Panel (ATP)-III
criteria [6]: levels of fasting plasma glucose >5.5mmol/L,
triglycerides 1.5mmol/L, high-density lipoprotein (HDL)-
cholesterol <1.0mmol/L (men) or <1.3mmol/L (women),
systolic blood pressure (BP) 130mmHg or diastolic BP
85mmHg or on BP-lowering medication, and waist cir-
cumference >102 cm (men) or >88 cm (women).
Participants were recruited to a randomized controlled diet-
ary intervention trial, performed in eight European centres
as part of the EU 6th Framework integrated project ‘Diet,
genomics and the metabolic syndrome – LIPGENE’. Details
of the study design and main results have been published
previously [7–9]. In this study, we have only used data from
the baseline investigations. Study exclusion criteria were
pre-diagnosed diabetes, inflammatory diseases, use of statins
and anti-inflammatory drugs, fatty acid supplements, alcohol
abuse and recent weight change 3 kg. The study was
approved by local ethics committees at each of the eight
intervention centres (Dublin, Reading, Oslo, Marseille,
Maastricht, Cordoba, Krakow and Uppsala), and written
consent was obtained from all study participants.
Cohort II included 62 men and women >18 years of age
with established T2D of Nordic or South Asian ethnicity,
recruited to a randomized placebo-controlled vitamin D
intervention trial. Details of the study design and main
results have been published previously [10,11]. In this study,
we have only used data from the baseline examinations.
Exclusion criteria were: plasma concentrations of 25(OH)D3
>50 nmol/L, serum levels of free calcium >1.35mmol/L,
HbA1c >11%, autoimmune diabetes and BMI >45 kg/m2.
Subjects with malignancy, a history of kidney stones, cardio-
vascular events during the past 6 months, glomerular filtra-
tion rate <30mL/min/1.73m2, BP>160/100mmHg, or
chronic inflammatory disease in an active phase, or preg-
nant and lactating women were not allowed to participate.
The study was approved by the Regional Committee for
Medical and Health Research Ethics (REK Sør-Øst) and
adhered to the Declaration of Helsinki. All participants gave
written, informed consent before any study-
related procedure.
Methods
In cohort I, an insulin-modified intravenous glucose toler-
ance test (IVGTT) was performed. After an overnight fast a
catheter was inserted into an antecubital vein for blood
sampling and into a contralateral antecubital vein for glu-
cose and insulin infusion. At time 0, 0.3 g/kg bodyweight of
a 500mg/mL glucose suspension was injected intravenously,
and after 20min a bolus of 0.03 IU/kg bodyweight of human
insulin (Actrapid, NovoNordisk, Bagsvaerd, Denmark) was
injected. Blood samples were drawn before, and 2, 4, 8, 19,
22, 30, 40, 50, 70, 90 and 180min after the initial glucose
injection. The MINMOD Millenium Programme version
6.02 (Richard N Bergman) was used to estimate insulin sen-
sitivity (SI). The first phase insulin secretion was defined as
the incremental area under the curve from time 0–8min
(iAUC0–8min) i.e. the acute insulin response to glucose
(AIRg). DI, insulin secretion adjusted for insulin sensitivity,
was calculated as the product of SI and iAUC0–8min. IVGTT
modelling was performed according to a pre-specified stand-
ard operating procedure and 434 subjects had accept-
able models.
BP was measured using an automatic BP measuring
device. Measurements were taken with an appropriate-size
cuff positioned on the upper arm at the level of the heart,
and the patient had been resting for at least five minutes.
The same arm was used for each measurement, at least two
measurements were performed at each visit, and the average
value was used for data processing.
All laboratory samples and clinical investigations were
taken, processed and stored in accordance with the study-
specific standard operating procedure. Body composition
was measured by bio-impedance methodology [8].
In cohort II, insulin secretion was similarly estimated as
first phase insulin response to glucose after an IVGTT, but
insulin sensitivity was measured by euglycaemic-hyperinsuli-
naemic clamp with infusion of deuterium labelled glucose to
estimate endogenous glucose production before and during
clamp. Briefly, a primed continuous infusion of [6,6-2H2]-
glucose (Cambridge Isotope Laboratories, Andover, MA)
was maintained throughout the experiment. After a 2-h
tracer equilibration period, the IVGTT was performed,
where 0.3 g/kg bodyweight of a 500mg/mL glucose suspen-
sion was injected intravenously and blood was drawn for
measurements of plasma glucose and serum insulin at 0, 2,
4, 6, 8, 10, 15, 20 and 30min. Insulin secretion was calcu-
lated as iAUC0–8min. Insulin secretion adjusted for insulin
sensitivity (DI) was calculated as the product of incremental
iAUC0–8min and clamp total glucose disposal (TGD) in
mmol/kg fat-free mass per minute.
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Immediately after the IVGTT, the euglycaemic clamp was
started with an insulin infusion rate of 80mU/m2/min,
using human insulin (Actrapid; Novo Nordisk, Bagsvaerd,
Denmark). A variable infusion of glucose 200mg/mL
enriched with 8mg [6,6-2H2]glucose/g glucose was continu-
ally adjusted to maintain euglycaemia. The clamp was main-
tained for at least 150min until at least 30min of stable
euglycaemia was obtained. At the end of the clamp, three
measurements of serum insulin and plasma deuterated glu-
cose concentrations were performed at 10min intervals. The
glucose infusion rate (GIR) in mmol/kg FFMmin was cal-
culated. Endogenous glucose production (EGP) was esti-
mated at the end of the basal equilibrium period and at the
end of the euglycaemic-hyperinsulinaemic clamp. At both
measurements, plasma glucose was in steady state, with only
minor variations in plasma glucose and tracer concentra-
tions. Based on this, steady state equations were used, with
the rate of supply corresponding to rate of disappearance to
calculate EGP and TGD. Insulin sensitivity was calculated as
TGD, including both the exogenous GIR and EGP.
Whole blood glucose concentration was measured by the
glucose oxidase method (YSI 2300; Yellow Springs
Instruments, Yellow Springs, OH), and plasma glucose was
calculated (whole blood glucose  1.119). [6,6-2H2]glucose
was measured by liquid chromatography combined with
tandem mass spectrometry (Sciex API 3000; Applied
Biosystems, Foster City, CA) at the Clinical Metabolomics
Core Facility (Rigshospitalet, Copenhagen, Denmark).
In both cohorts, routine clinical chemistry methods were
used for measurements of HbA1c, glucose, lipids, C-peptide
and insulin. The HOMA2 calculator version 2.2.2 (https://
www.dtu.ox.ac.uk/homacalculator. . . . . . . ) was used to cal-
culate HOMA2-IR and HOMA2-B values based on fasting
glucose and C-peptide. The calculator can only be used for
fasting C-peptide from 0.2 to 3.5 nmol/L and fasting blood
glucose from 3.0 to 25.0mmol/L [12]. Individuals with val-
ues outside these ranges were excluded from the calcula-
tions. In cohort I, 79 individuals had fasting C-peptide
values >3.5 nmol/L.
Clustering analysis
Data-driven cluster analysis (k-means) was performed in the
MetS cohort. Clusters were based on four variables (age,
BMI, HOMA2-IR and HOMA2-B). The optimal number of
clusters for k-means clustering was k¼ 4 using factoextra
and the elbow-method in R version 3.6.0 ((R Foundation
for Statistical Computing, Vienna, Austria). Testing differen-
ces in the four variables between patients in the identified
clusters were performed using ANOVA with Tukey’s HSD
post hoc correction for multiple testing.
Statistical analysis
Data are presented as means ± SD unless otherwise specified.
Student’s t tests were used for comparison of two groups,
and Mann–Whitney U tests were used for comparison of
two independent groups where the measured parameter did
not follow a normal distribution. A two-sided p< .05 was
deemed significant. Ranges of the different parameters of
insulin secretion and action and MetS were examined by
reporting the lowest and the highest values of the entire
cohort. To avoid that few individuals and errors will have a
decisive impact, truncated range after exclusion of the
extreme values, <5th and >95th percentiles, are also given.
Fold variation was calculated as the 95th percentile divided
by the absolute value of the 5th percentile. To assess the
relationship between insulin secretion and sensitivity, we
performed model selection by constructing a simple linear
model (y x) and several non-linear negative exponential
models (y xb), where b ranged from 0.1 to 1 (hyperbola),
as well as a log-hyperbola function (y log(1/x)). The dif-
ferent models were evaluated against each other by perform-
ing analysis of variance (ANOVA). We used the IBM SPSS
Statistics version 24 (SPSS, Chicago, IL) and R version 3.5.3
software packages.
Results
Clinical characteristics of the two cohorts are shown in
Tables 1 and 2. There were 220 men and 266 women in
Table 1. Clinical characteristics of subjects in Cohort I.
All Men Women
n¼ 486 n¼ 220 n¼ 266
Age (years) 54.5 ± 9.1 53.4 ± 9.8 55.5 ± 8.0
BMI (kg/m2) 32.3 ± 4.4 32.0 ± 3.8 32.7 ± 4.4
Waist circumference (cm) 106.1 ± 11.8 110.9 ± 9.9 102.6 ± 10.5
Hip circumference (cm) 112.7 ± 10.0 110.0 ± 9.0 115.3 ± 10.2
Waist-hip-ratio 0.9 ± 0.1 1.0 ± 0.1 0.9 ± 0.1
Fat (kg) 33.2 ± 9.3 29.9 ± 8.5 36.0 ± 8.8
Body fat percentage (%) 36.5 ± 8.8 29.9 ± 5.6 41.9 ± 6.8
Fat free mass (kg) 56.6 ± 13.8 68.3 ± 10.2 47.3 ± 7.6
F-plasma glucose (mmol/L) 6.0 ± 0.8 6.0 ± 0.8 5.9 ± 0.8
F-TAG (mmol/L)a 1.59 (1.17, 2.23) 1.63 (1.18, 2.23) 1.56 (1.17, 2.21)
F-HDL cholesterol (mmol/L) 1.10 ± 0.29 0.98 ± 0.22 1.20 ± 0.29
Systolic BP (mmHg) 139 ± 15 139 ± 14 138 ± 15
Diastolic BP (mmHg) 86 ± 9 88 ± 9 85 ± 9
BMI: body mass index; F: fasting; TAG: triglyceride; HDL: high-density lipopro-
tein; BP: blood pressure.
Data represent means ± SD.
aMedian (25% percentile, 75% percentile).
Table 2. Clinical characteristics of subjects in cohort II.
All Men Women
n¼ 62 n¼ 37 n¼ 25
Age (years) 55.7 ± 9.4 57.1 ± 9.2 53.5 ± 9.2
BMI (kg/m2) 31.9 ± 4.9 31.1 ± 4.1 33.0 ± 5.7
Waist circumference (cm) 109.2 ± 12.4 110.2 ± 10.9 107.8 ± 14.2
Hip circumference (cm) 105.4 ± 9.3 104.3 ± 7.7 107.0 ± 11.1
Waist-hip-ratio 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1
Body fat percentage (%) 33.5 ± 8.3 28.2 ± 4.1 41.2 ± 6.7
Fat free mass (kg) 60.8 ± 12.6 68.3 ± 10.0 49.6 ± 6.4
HbA1c (mmol/mol) 62 ± 14 61 ± 14 63 ± 15
Diabetes duration (years) 10.0 ± 6.4 9.8 ± 6.9 10.2 ± 5.5
F-plasma glucose (mmol/L) 10.7 ± 3.3 10.4 ± 3.1 11.1 ± 3.6
F-TAG (mmol/L)a 1.3 (0.9, 2.0) 1.3 (0.9, 2.0) 1.3 (0.9, 1.9)
F-HDL cholesterol (mmol/L) 1.0 ± 0.3 1.0 ± 0.2 1.1 ± 0.3
Systolic BP (mmHg) 128 ± 15 131 ± 14 122 ± 16
Diastolic BP (mmHg) 84 ± 9 86 ± 9 82 ± 9
BMI: body mass index; F: fasting; TAG: triglyceride; HDL: high-density lipopro-
tein; BP: blood pressure.
Data represent means ± SD.
aMedian (25% percentile, 75% percentile).
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cohort I, with a mean (±SD) age of 54.5 ± 9.1 years and
BMI 32.3 ± 4.4 kg/m2. Of the total cohort, 95 individuals
(19.6%) qualified for all five criteria of MetS, according to
the NCEP III definition [6], and 409 individuals (84.2%) for
three or more of the criteria. Although established diabetes
was an exclusion criterion for participating in cohort I, 46
individuals had a single fasting glucose measurement of
7mmol/L or higher at the day of investigation. In cohort II,
there were 37 men and 25 women with a mean (±SD) age
of 55.7 ± 9.4 years, BMI 31.9 ± 4.9 and duration of diabetes
of 10.0 ± 6.4 years. In cohort II, 10 patients were non-
pharmacologically treated and 52 used insulin and/or oral
antihyperglycaemic agents. Eleven of the participants in this
cohort (17.7%) qualified for all five criteria of MetS and 48
individuals (77.4%) qualified for three or more of
the criteria.
Insulin secretion
There was a large inter-individual variation in measures of
insulin secretion, measured as AUC0–8min, DI and HOMA2-
B among the participants in both cohorts. Figure 1 shows
individual data for insulin secretion measured as HOMA2-B
and AUC0–8min, and Table 3 shows the inter-individual
variation for different parameters of insulin secretion in the
two cohorts. In cohort I, HOMA2-B ranged from 67% to
992%. Insulin secretion, measured as iAUC0–8min, ranged
Figure 1. Individual data for insulin secretion. Measured as HOMA2-B in cohort I (A) and cohort II (B), and as iAUC0–8 min in cohort I (C) and in cohort II (D).
iAUC0–8 min: incremental area under the curve for the first phase (0–8min) insulin response to glucose.
Table 3. Variation in insulin secretion indices for subjects in cohorts I and II.
Cohort I Cohort II
Variation
Variation in 5th and
95th percentiles
Fold variation
5th and 95th
percentilesa Variation
Variation in 5th and
95th percentiles
Fold variation
5th and 95th
percentilesa
HOMA2-B (%) 67–992 135–353 2.6 15–153 18–122 6.9
iAUC0–8 min (mU L
1min1) 60–3397 18–750 40.7 263–1194 75–882 11.8
DIb 89–4053 53–2330 37.0 5238–43,818 3416–31,188 9.1
aTruncated range was calculated after exclusion of extreme values (<5th and >95th percentiles), and the fold variation calculated as the 95th percentile divided
by the absolute value of the 5th percentile.
DI: disposition index, iAUC0–8 min: incremental area under the curve for the first phase (0–8min) insulin response to glucose.
bValues for DI in cohort I and II are not comparable due to different estimates of insulin sensitivity.
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from 60 to 3397mU L1min1. DI had the greatest spread
of all measurements, with a range from 89 to 4053.
Among participants in cohort II, the HOMA2-B ranged
from 15% to 153%, iAUC0–8min from 263 to 1194mU
L1min1 and DI from 5238 to 43,818.
Insulin action
The inter-individual variations in indices of insulin resist-
ance, measured as fasting insulin, fasting C-peptide,
HOMA2-IR, SI, GIR and TGD were also substantial, but
tended to be smaller than for indices of insulin secretion.
Figure 2 shows individual data for insulin resistance meas-
ured as HOMA-IR in both cohorts and SI in cohort I and
TGD in cohort II. Table 4 displays the inter-individual vari-
ation for some parameters of insulin action in the two
cohorts. In cohort I, the measures of SI ranged from 0.19 to
15.29 (mU/L)1min1 and in cohort II, TGD ranged from
12.9 to 101.6lmol kgFFM1min1.
In order to put the large inter-individual variation in the
measures of insulin secretion and sensitivity into perspec-
tive, we also calculated the inter-individual variation and
fold variation in components of MetS (Table 5). In cohort I,
the truncated fold variations were 1.5 for fasting plasma
Figure 2. Individual data for insulin resistance. Measured as HOMA2-IR in cohort I (A) and cohort II (B), and as SI in cohort I (C) and as TGD in cohort II (D).
HOMA2-IR: homeostatic model assessment for insulin resistance, SI: insulin sensitivity index; TGD: total glucose disposal.
Table 4. Variation in insulin resistance or insulin sensitivity indices for subjects in cohorts I and II.
Cohort I Cohort II
Variation
Variation in 5th and
95th percentiles
Fold variation
5th and 95th
percentilesa Variation
Variation in 5th and
95th percentiles
Fold variation
5th and 95th
percentilesa
F-insulin (mU/L) <2.5–42.7 4.0–20.5 5.1 3.3–138.3 4.7–38.0 8.1
F-C-peptide (pmol/L) 271–1987 350–1410 3.1 312–2289 513–1832 3.6
HOMA2-IR 2.3–8.9 3.1–8.3 2.6 0.8–5.6 1.5–4.9 3.3
SI ((mU/L)
1min1) 0.19–15.29 0.86–5.85 6.8 NA NA NA
GIR (lmol kgFFM1 min1) NA NA NA 1.2–76.3 5.6–50.6 9.0
TGD (lmol kgFFM1 min1) NA NA NA 12.9–101.6 15.1–82.5 5.5
aTruncated range was calculated after exclusion of extreme values (<5th and 95th percentiles), and fold variation calculated as the 95th percentile divided by
the absolute value of the 5th percentile was the highest value divided by the lowest value after truncation.
SI: sensitivity index; GIR: glucose infusion rate; FFM: fat free mass; TGD: total glucose disposal; NA: not applicable.
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glucose, 4.1 for triglycerides and 1.5 for BMI.
Corresponding findings in cohort II were 2.6 for glucose,
4.7 for triglycerides and 1.6 for BMI.
Relationship between insulin sensitivity and
insulin response
Plotting individual data of insulin sensitivity (SI) and insulin
secretion (iAUC0–8min) revealed a hyperbolic relationship in
normoglycaemic individuals from cohort I, as expected
based on the studies of Pacini [13] and Ahren and Pacini
[14] (Figure 3). In our data, the log-hyperbola function
exhibited a superior data fit with the smallest sum of
squared errors (SSE) of prediction, as based on ANOVA for
model selection. Figure 3 demonstrates that individuals with
impaired fasting plasma glucose or diabetic glucose range
did ‘fall off the hyperbolic curve’ [5]. In addition, Figure 3
reveals that several individuals with abnormal fasting plasma
glucose values had insulin secretion and insulin sensitivity
estimates indistinguishable from normoglycaemic
individuals.
Data-driven k means clustering in the MetS cohort
We identified four clusters of patients with MetS, which had
significantly different patient characteristics (Figure 4). In
particular, individuals in cluster 1–4 exhibited decreasing
age, and increasing BMI, HOMA-B and HOMA-IR (Figure
4(A)). The optimal number of clusters was chosen using the
elbow-method (Figure 4(B)). Principal component analysis
separated the means of four clusters using the first and
second dimension (Figure 4(C)) at a confidence level
of 99%.
Discussion
Although subjects with prediabetes and T2D display insulin
resistance and reduced first-phase insulin secretion as com-
pared to groups of normoglycaemic subjects, we show that
there is an extensive inter-individual variation in both these
parameters, with substantial overlap between groups. The
individual variation in insulin resistance and first-phase
insulin secretion were considerably larger than the variabil-
ity in the common components used to characterize MetS.
Furthermore, we observed a log-hyperbolic relationship
between insulin secretion and sensitivity in normoglycaemic
subjects, consistent with previous reports [13,14]. This rela-
tionship indicates that insulin sensitivity is reduced with
increasing hyperinsulinaemia, but after a certain threshold,
which is different for each individual, even excessive insulin
secretion results in near undetectably increased insulin sen-
sitivity. Hence, the hyperbolic relationship fits well with the
underlying biological processes for insulin signalling, such
as thresholds and saturation of enzymatic reactions.
Surprisingly few studies have reported individual data
and analysed the variation in insulin secretion and action
depending on different degrees of glucose intolerance.
However, a number of studies have reported insulin secre-
tion and sensitivity in groups of normoglycaemic individuals
[5,15–21]. Bardet et al. [21] reported large inter- and intra-
individual variability in AIRg measured by IVGTT in 41
Table 5. Variation in components of the metabolic syndrome for subjects in cohorts I and II.
Cohort I Cohort II
Variation
Variation in 5th and
95th percentiles
Fold variation
5th and 95th
percentilesa Variation
Variation in 5th and
95th percentiles
Fold variation
5th and 95th
percentilesa
F-glucose (mmol/L) 3.1–10.3 4.7–8.2 1.5 5.7–19.7 6.5–16.8 2.6
F-TAG (mmol/L) 0.42–7.11 0.82–3.35 4.1 0.6–4.7 0.7–3.3 4.7
HDL cholesterol (mmol/L) 0.47–2.33 0.72–1.59 2.2 0.7–1.9 0.7–1.5 2.1
Systolic BP (mmHg) 105–189 117–164 1.4 96–164 101–154 1.5
Diastolic BP (mmHg) 62–118 71–101 1.4 63–107 69–98 1.4
Waist circumference (cm) 70.0–174.7 88.0–127.7 1.4 79.3–39.5 92.4–126.9 1.4
BMI (kg/m2) 21.1–45.3 25.5–40.0 1.5 21.8–42.0 25.4–40.3 1.6
aTruncated range was calculated after exclusion of extreme values (<5th and >95th percentiles), and the fold variation calculated as the 95th percentile divided
by the absolute value of the 5th percentile.
TAG: triacylglycerol; HDL: high-density lipoprotein; BP: blood pressure; BMI: body mass index.
Figure 3. Relationship between insulin sensitivity (SI) and first-phase insulin
secretion (iAUC) across different categories of fasting plasma glucose in cohort
1. Green points: subjects with fasting plasma glucose <5.6mmol/L, orange
points: subjects with fasting plasma glucose 5.6–7.0mmol/L and red points:
subjects with fasting plasma glucose >7.0mmol/L. The green trend line shows
the log-hyperbola relationship between insulin sensitivity and secretion within
those with normal fasting plasma glucose. iAUC0–8 min: incremental area under
the curve for the first phase (0–8min) insulin response to glucose.
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healthy volunteers [21]. Their results suggest that AIRg
should be interpreted with caution even in normoglycaemic
individuals due to the large variation. A population-based
study of 380 young healthy Caucasians from Denmark
reported that the insulin sensitivity index (SI) varied widely
[15]. The distribution of SI was skewed to the right, and the
variation in SI was highest among the leanest subjects [15].
About one-third of the variation in SI could be explained by
body fat, maximum aerobic capacity, and women’s use of
oral contraceptives [15]. The strength of our study is a large
number of individuals investigated with appropriate meth-
ods for measuring insulin secretion and sensitivity. Few
studies of similar size have examined inter-individual
variation with appropriate methods. IVGTT and subsequent
minimal modelling is a well-known tool for estimating insu-
lin sensitivity and insulin secretion, and the euglycaemic
hyperinsulinaemic clamp is considered a gold standard to
determine insulin sensitivity [22].
The glucose clamp depends on steady state, whereas the
minimal model technique uses dynamic data. IVGTT-based
SI correlates well with insulin sensitivity estimates from the
euglycaemic clamp in healthy subjects, but correlates poorer
among subjects with overweight, impaired glucose tolerance
or T2D [23]. Another limitation of the IVGTT is that it
requires a greater insulin response than clamp to get a pre-
cise estimate of insulin sensitivity, and this limits the use
among individuals with insulin deficiency. It can be argued
that IVGTT is not the optimal method for measuring insu-
lin secretion in individuals with hyperglycaemia because the
first-phase insulin secretion (AIRg) often disappears at fast-
ing plasma glucose concentrations >7.0mmol/L [23].
However, an interesting finding in this study is that many
people with fasting hyperglycaemia and even established
diabetes still have significant first-phase insulin secre-
tion intact.
Cohort I was a multi-centre study and the eight interven-
tion centres used different recruitment strategies for partici-
pants in the study [7,8]. This may contribute to the
observed variations. On the other hand, such a pan-
European multi-centre study may increase the generalizabil-
ity of the findings. Only individuals with Caucasian
ethnicity participated in the LIPGENE study, which limits
the generalizability to such individuals.
Another consideration that should be taken into account
when interpreting the results is that participants in cohort I
were selected to have MetS, which favours the inclusion of
subjects with insulin resistance, although not all the individ-
uals included in cohort I can be classified as insu-
lin resistant.
Participants in cohort I were selected for vitamin D defi-
ciency, and although vitamin D deficiency is fairly common,
at least during the winter, this criterion may limit the
extrapolation of our results to the general population of
T2D patients. However, we found no effect of vitamin D
supplementation on insulin secretion and action in our
study [11].
For the components of MetS, the variation in measure-
ments between individuals was less than the variation in
measurements of insulin sensitivity and resistance. The
inter-individual variability is somewhat greater in the partic-
ipants in cohort I than in cohort II. It is uncertain whether
a single primary abnormality triggers a cascade of various
events leading to manifestation of MetS, but some evidence
suggests insulin resistance as the main defect linking the
various components of MetS. The strength of this correl-
ation varies between, and also within, different popula-
tions [2].
It may be important to investigate whether more sophis-
ticated methods to measure insulin secretion and action as
reported in our present paper can contribute to improved
phenotypic characterization of T2D. Being aware of the
Figure 4. Distribution of MetS patients (n¼ 486) according to k-means cluster-
ing. (A) Pairwise comparison of age, BMI, HOMA-B and HOMA-IR between
patients in the identified four clusters. The comparison was made using ANOVA
with Tukey HSD post hoc correction for multiple testing. (B) The optimal num-
ber of clusters was chosen using the elbow-method. (C) Clustering of patients
according to k means and principal component analysis. p< .001, p< .01
and p< .05. N.S: not significant. Tot. SS: total within the sum of squares.
Dim1/2¼ principal component 1/2.
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large inter-individual variation at different degrees of glu-
cose tolerance may be important for understanding T2D
and possible underlying disease mechanisms. Different indi-
viduals may have a different clinical course, risk of compli-
cations and the need for different types of treatment.
It is well known that T2D is a heterogeneous disease
with regard to clinical presentation, progression and prob-
ably underlying disease mechanisms. Several studies have
attempted to subclassify the T2D population based on
pathophysiological subphenotypes with the ultimate aim
able to individualize diabetes treatment. Ahlqvist et al. pro-
posed in 2018 a new classification of T2D into five sub-
groups with different characteristics, and risk of diabetic
complications [24]. The subgroups were based on cluster
analysis of six variables; the presence of autoantibodies, age
at diagnosis, BMI, HbA1c, HOMA2-IR and HOMA2-B. The
different clusters had significantly different patient charac-
teristics and risk of diabetic complications such as diabetic
kidney disease and diabetic retinopathy. Based on the classi-
fication suggested by Ahlquist et al., Zaharia et al. subclassi-
fied 1105 patients with newly diagnosed T1D or T2D in the
German Diabetes Study into five clusters [25]. They wanted
to see if there was any association between cluster assign-
ment and risk of diabetic neuropathy and non-alcoholic
fatty liver disease (NAFLD) within 5 years after diagnosis.
The prevalence of diabetes complications at early stages of
NAFLD and diabetes neuropathy were also different in spe-
cific diabetic clusters.
In 2018, Stidsen et al. subphenotyped 4285 Danish patients
with newly diagnosed T2D after WHO’s definition of T2D
according to their beta-cell function, measured as HOMA-B,
and insulin sensitivity, measured as HOMA-S [26]. The
patients were subclassified into insulinopenic T2D (low IS
and low b-cell function), classical T2D (low IS and low b-cell
function) and hyperinsulinemic T2D (low IS and low b-cell
function). These researchers also examined the association
between different T2D subphenotypes and important clinical
characteristics such as age, gender, waist circumference and
history of cardiovascular morbidity. There was a clinically sig-
nificant difference in cardiovascular morbidity and waist cir-
cumference between the groups. All these findings support
the notion that targeted treatment and prevention for diabetes
complications may be more beneficial than treating all
patients with T2D equally. We used a similar cluster-analysis
approach and show a trend for clustering; however, the over-
lap between the clusters are substantial and we have no long-
term outcome data from our cohorts to evaluate the predict-
ive power of this clustering.
In conclusion, our data demonstrated extensive inter-
individual variation in insulin secretion and somewhat less
in insulin sensitivity. These inter-individual variations are
essential to take into account when planning clinical
research and treatment in subjects with MetS or T2D.
Acknowledgements
We thank the participants and the staff at all the clinical centres for
their enthusiasm and support: Trinity College Dublin/University
College Dublin, Ireland, University of Reading, UK, Oslo University
Hospital Aker/University of Oslo, Norway, INSERM, Marseille, France,
Maastricht University, The Netherlands Hospital Universitario Reina
Sofıa/University of Cordoba, Spain, Jagiellonian Medical College,
Krakow, Poland and Uppsala University, Sweden. The authors also
thank research nurses Åse Halsne and Gøril Vinje at Oslo University
Hospital, Professor Gerrit Van Hall at the Clinical Metabolomics Core
Facility, Rigshospitalet, Copenhagen, Denmark and the Simon Fougner
Hartmann Foundation.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
Cohort I – the LIPGENE study - an EU 6th Framework Program
Integrated Project (FOOD-CT-2003-505944) was also supported by
grants from: the Norwegian Foundation for Health and Rehabilitation,
South-Eastern Norway Regional Health Authority, the Norwegian
Diabetic Association, Freia Medical Foundation and Johan Throne
Holst Foundation for Nutrition Research, Norway. Cohort II was sup-
ported by grants from: the Norwegian Extra Foundation, the South-
Eastern Norway Regional Health Authority and the Norwegian
Diabetes Association.
ORCID
Sindre Lee http://orcid.org/0000-0002-0670-7555
References
[1] Ferrannini E, Mari A. Beta cell function and its relation to
insulin action in humans: a critical appraisal. Diabetologia.
2004;47(5):943–956.
[2] Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syn-
drome. Lancet. 2010;375(9710):181–183.
[3] Ferrannini E, Gastaldelli A, Miyazaki Y, et al. Beta-cell function
in subjects spanning the range from normal glucose tolerance
to overt diabetes: a new analysis. J Clin Endocrinol Metab.
2005;90(1):493–500.
[4] Marchetti P, Lupi R, Del Guerra S, et al. The beta-cell in
human type 2 diabetes. Adv Exp Med Biol. 2010;654:501–514.
[5] Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of
the relationship between insulin sensitivity and beta-cell func-
tion in human subjects. Evidence for a hyperbolic function.
Diabetes. 1993;42(11):1663–1672.
[6] Third Report of the National Cholesterol Education Program
(NCEP). Expert panel on detection, evaluation, and treatment
of high blood cholesterol in adults (adult treatment panel III)
final report. Circulation. 2002;106:3143–3421.
[7] Shaw DI, Tierney AC, McCarthy S, et al. LIPGENE food-
exchange model for alteration of dietary fat quantity and qual-
ity in free-living participants from eight European countries. Br
J Nutr. 2008;101(5):750–759.
[8] Tierney AC, McMonagle J, Shaw DI, et al. Effects of dietary
fat modification on insulin sensitivity and on other risk
factors of the metabolic syndrome–LIPGENE: a European
randomized dietary intervention study. Int J Obes. 2011;35(6):
800–809.
[9] Gulseth HL, Gjelstad IMF, Tiereny AC, et al. Effects of dietary
fat on insulin secretion in subjects with the metabolic syn-
drome. Eur J Endocrinol. 2019;180(5):321–328.
[10] Wium C, Gulseth HL, Eriksen EF, et al. Characteristics of glu-
cose metabolism in Nordic and South Asian subjects with type
2 diabetes. PLoS One. 2013;8(12):e83983.
8 A. M. B. HANSEN ET AL.
[11] Gulseth HL, Wium C, Angel K, et al. Effects of vitamin D sup-
plementation on insulin sensitivity and insulin secretion in sub-
jects with type 2 diabetes and vitamin D deficiency: a
randomized controlled trial. Diabetes Care. 2017;40(7):872–878.
[12] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA
modeling. Diabetes Care. 2004;27(6):1487–1495.
[13] Pacini G. The hyperbolic equilibrium between insulin sensitiv-
ity and secretion. Nutrition, metabolism, and cardiovascular
diseases. NMCD. 2006;16:S22–S27.
[14] Ahren B, Pacini G. Importance of quantifying insulin secretion
in relation to insulin sensitivity to accurately assess beta cell
function in clinical studies. Eur J Endocrinol. 2004;150:97–104.
[15] Clausen JO, Borch-Johnsen K, Ibsen H, et al. Insulin sensitivity
index, acute insulin response, and glucose effectiveness in a
population-based sample of 380 young healthy Caucasians.
Analysis of the impact of gender, body fat, physical fitness, and
life-style factors. J Clin Invest. 1996;98(5):1195–1209.
[16] Martin BC, Warram JH, Krolewski AS, et al. Role of glucose
and insulin resistance in development of type 2 diabetes melli-
tus: results of a 25-year follow-up study. Lancet. 1992;
340(8825):925–929.
[17] Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and
insulin secretory dysfunction as precursors of non-insulin-
dependent diabetes mellitus. Prospective studies of Pima
Indians. N Engl J Med. 1993;329(27):1988–1992.
[18] Hollenbeck C, Reaven GM. Variations in insulin-stimulated
glucose uptake in healthy individuals with normal glucose tol-
erance. J Clin Endocrinol Metab. 1987;64(6):1169–1173.
[19] Allemann Y, Horber FF, Colombo M, et al. Insulin sensitivity
and body fat distribution in normotensive offspring of hyper-
tensive parents. Lancet. 1993;341(8841):327–331.
[20] Osei K, Cottrell DA, Orabella MM. Insulin sensitivity, glucose
effectiveness, and body fat distribution pattern in nondiabetic
offspring of patients with NIDDM. Diabetes Care. 1991;14(10):
890–896.
[21] Bardet S, Pasqual C, Maugendre D, et al. Inter and intra
individual variability of acute insulin response during intraven-
ous glucose tolerance tests. Diabetes Metab. 1989;15(5):
224–232.
[22] Clinical Diabetes Research: Methods and techniques.
Chichester: John Wiley & Sons, Ltd; 2007.
[23] Mari A, Tura A, Pacini G, et al. Relationships between insulin
secretion after intravenous and oral glucose administration in
subjects with glucose tolerance ranging from normal to overt
diabetes. Diabet Med. 2008;25(6):671–677.
[24] Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of
adult-onset diabetes and their association with outcomes: a
data-driven cluster analysis of six variables. Lancet Diabetes
Endocrinol. 2018;6:361–369.
[25] Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-
associated diseases in subgroups of patients with recent-onset
diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol.
2019;7:684–694.
[26] Stidsen JV, Henriksen JE, Olsen MH, et al. Pathophysiology-
based phenotyping in type 2 diabetes: a clinical classification
tool. Diabetes Metab Res Rev. 2018;34(5):e3005.
SCANDINAVIAN JOURNAL OF CLINICAL AND LABORATORY INVESTIGATION 9
